Increased survival rate of severely ill patients nearly 3 times
Yet another study has supported former President Trump’s suggestion that the common malaria drug hydroxychloroquine is an effective treatment for COVID-19.
This time, a study on 255 patients by St Barnabas Medical Center in New Jersey found that when used in a high dosage and with zinc, the drug increased survival rates nearly three times for severe cases in which patients were on ventilators.
Establishment media mocked Trump in April 2020 when he said hydroxychloroquine is a “powerful drug on malaria, and there are signs that it works on [the coronavirus], some very strong signs.”
A month later, he told attendees during a roundtable event at the White House that he “happen to be taking it” as a preventative.
“A lot of good things have come out. You’d be surprised at how many people are taking it, especially the front-line workers,” he said. “Before you catch it. The front-line workers, many, many are taking it.”
In March, the World Health Organization issued a warning against using the drug to treat COVID-19. And last month, the Canadian Global Television Network called hydrochloroquine and ivermectin “two drugs that conspiracy theorists say cure COVID-19 and that scientists say are useless at treating the disease.”
But there are 219 peer-reviewed studies indicating the effectiveness of hydroxychloroquine as a treatment and prophylaxis against COVID-19. And 54 peer-reviewed studies show the effectiveness of ivermectin.
A study by International Journal of Antimicrobial Agents published in December found hospitalizations were reduced 84% when COVID patients were treated with hydroxychloroquine.